SCHEMBL30009910

SCHEMBL30009910

CC1C=CCN(C(=O)c2cc(Cl)nc(Cl)c2)C1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 2/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
PROKR1 Q8TCW9 2/20 0.36
GAA P10253 1/20 0.34
NPC1 O15118 2/20 0.33
HRH4 Q9H3N8 2/20 0.33
PLA2G7 Q13093 1/20 0.33
HSD17B10 Q99714 1/20 0.33
RAB9A P51151 1/20 0.33
HSD11B1 P28845 2/20 0.32
GLRA1 P23415 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
POLB P06746 1/20 0.32
ATXN2 Q99700 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30008788 0.93 PROKR1 (0.44) JAK1MEN1KMT2AALDH1A1NPSR1
SCHEMBL30009435 0.85 PROKR1 (0.49) PROKR1GAANPC1HSD17B10
SCHEMBL30009357 0.76 TSHR (0.38) ALDH1A1HRH4
SCHEMBL30009093 0.75 GAA (0.38) PROKR1GAANPC1PLA2G7HSD17B10
SCHEMBL30009886 0.74 JAK1 (0.39) JAK1MEN1KMT2AALDH1A1GAA
SCHEMBL30009231 0.74 TAS1R3 (0.43) PROKR1GAANPC1PLA2G7HSD17B10
SCHEMBL29336922 0.72 KDM4E (0.48) JAK1ALDH1A1PROKR1GAANPC1
SCHEMBL30008761 0.71 AKR1C4 (0.43) MEN1KMT2AALDH1A1GAAHSD17B10
SCHEMBL30009010 0.70 LMNA (0.45) JAK1KMT2AALDH1A1HRH3
SCHEMBL6578719 0.69 POLB (0.60) MEN1KMT2AALDH1A1HRH4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 JAK1 83/4885MEN1 843/4885KMT2A 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.